MY205197A - Methyllactam ring compound and pharmaceutical use thereof - Google Patents

Methyllactam ring compound and pharmaceutical use thereof

Info

Publication number
MY205197A
MY205197A MYPI2020003891A MYPI2020003891A MY205197A MY 205197 A MY205197 A MY 205197A MY PI2020003891 A MYPI2020003891 A MY PI2020003891A MY PI2020003891 A MYPI2020003891 A MY PI2020003891A MY 205197 A MY205197 A MY 205197A
Authority
MY
Malaysia
Prior art keywords
methyllactam
pharmaceutical use
ring compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MYPI2020003891A
Other languages
English (en)
Inventor
Tomoya Miura
Yoshinori Tamatani
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MY205197A publication Critical patent/MY205197A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI2020003891A 2018-03-01 2019-02-28 Methyllactam ring compound and pharmaceutical use thereof MY205197A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018036307 2018-03-01
PCT/JP2019/007799 WO2019168096A1 (ja) 2018-03-01 2019-02-28 メチルラクタム環化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
MY205197A true MY205197A (en) 2024-10-07

Family

ID=67806229

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020003891A MY205197A (en) 2018-03-01 2019-02-28 Methyllactam ring compound and pharmaceutical use thereof

Country Status (21)

Country Link
US (3) US11014910B2 (enExample)
EP (1) EP3760624A4 (enExample)
JP (3) JP7206132B2 (enExample)
KR (1) KR102795351B1 (enExample)
CN (1) CN111757877B (enExample)
AR (1) AR114418A1 (enExample)
AU (1) AU2019227770B2 (enExample)
BR (1) BR112020016788A2 (enExample)
CA (1) CA3087859A1 (enExample)
CL (1) CL2020002199A1 (enExample)
IL (1) IL276311B2 (enExample)
MA (1) MA52427A (enExample)
MX (1) MX2020009070A (enExample)
MY (1) MY205197A (enExample)
PE (1) PE20210123A1 (enExample)
PH (1) PH12020551340A1 (enExample)
SA (1) SA520420037B1 (enExample)
SG (1) SG11202007120UA (enExample)
TW (1) TWI805699B (enExample)
WO (1) WO2019168096A1 (enExample)
ZA (1) ZA202004600B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
CN111902408B (zh) 2018-04-04 2023-11-14 日本烟草产业株式会社 杂芳基取代的吡唑化合物及其药物用途
CA3151909A1 (en) * 2019-09-04 2021-03-11 Japan Tobacco Inc. Therapeutic or prophylactic method for diabetes using combination medicine
JPWO2021187548A1 (enExample) * 2020-03-19 2021-09-23

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657282A (en) * 1969-01-23 1972-04-18 Merck & Co Inc Carboxyepoxyethyl-1-phosphonic acid and derivatives
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2515119A1 (en) 2003-02-07 2004-08-19 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivative
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
CN1980665A (zh) 2004-07-07 2007-06-13 默克公司 吡唑酰胺衍生物，包含这些化合物的组合物和使用方法
EP1811983B1 (en) 2004-11-16 2020-10-07 GW Pharma Limited New use for cannabinoid
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
CN101243074A (zh) * 2005-06-08 2008-08-13 日本烟草产业株式会社 杂环化合物
WO2006132436A1 (ja) 2005-06-08 2006-12-14 Japan Tobacco Inc. 複素環化合物
JP4137956B2 (ja) * 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
WO2007034279A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
JP2009523748A (ja) 2006-01-18 2009-06-25 シエナ ビオテク ソシエタ ペル アチオニ α７ニコチン性アセチルコリン受容体の調節物質およびそれらの治療への使用
EP2026798A1 (en) * 2006-04-27 2009-02-25 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
KR101450356B1 (ko) 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체
WO2008061796A2 (en) 2006-11-24 2008-05-29 Ac Immune Sa Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
KR101506935B1 (ko) * 2007-04-02 2015-03-31 테라코스, 인코포레이티드 벤질릭 글리코시드 유도체 및 사용 방법
US20090181952A1 (en) 2008-01-14 2009-07-16 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
TW201006832A (en) 2008-07-15 2010-02-16 Novartis Ag Organic compounds
RU2017144535A (ru) 2010-03-30 2019-02-18 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
CN111902408B (zh) 2018-04-04 2023-11-14 日本烟草产业株式会社 杂芳基取代的吡唑化合物及其药物用途

Also Published As

Publication number Publication date
AU2019227770A1 (en) 2020-07-09
US20190352284A1 (en) 2019-11-21
TWI805699B (zh) 2023-06-21
SG11202007120UA (en) 2020-08-28
ZA202004600B (en) 2022-03-30
CN111757877B (zh) 2023-10-27
MX2020009070A (es) 2020-10-08
AU2019227770B2 (en) 2023-10-05
JP2023026566A (ja) 2023-02-24
US20240174646A1 (en) 2024-05-30
IL276311A (en) 2020-09-30
SA520420037B1 (ar) 2024-07-28
MA52427A (fr) 2021-01-06
IL276311B1 (en) 2023-06-01
US20220064148A1 (en) 2022-03-03
KR20200128033A (ko) 2020-11-11
PE20210123A1 (es) 2021-01-19
EP3760624A4 (en) 2021-11-03
CA3087859A1 (en) 2019-09-06
KR102795351B1 (ko) 2025-04-16
CN111757877A (zh) 2020-10-09
WO2019168096A1 (ja) 2019-09-06
PH12020551340A1 (en) 2021-05-31
BR112020016788A2 (pt) 2021-01-12
CL2020002199A1 (es) 2020-12-18
RU2020131756A (ru) 2022-03-28
IL276311B2 (en) 2023-10-01
EP3760624A1 (en) 2021-01-06
AR114418A1 (es) 2020-09-02
US11014910B2 (en) 2021-05-25
JP2019151627A (ja) 2019-09-12
TW202000660A (zh) 2020-01-01
JP7206132B2 (ja) 2023-01-17
JP2025026615A (ja) 2025-02-21

Similar Documents

Publication Publication Date Title
PH12019501685A1 (en) Quinazone compound
ZA202206923B (en) New methylquinazolinone derivatives
PH12016502103B1 (en) Novel disubstituted 1,2, 4-triazine compound
MY205197A (en) Methyllactam ring compound and pharmaceutical use thereof
PH12016502246B1 (en) Carboxamide derivatives
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
MX2021007247A (es) Derivados de rapamicina.
MX2018014813A (es) Composiciones antibacterianas.
PH12020550253A1 (en) Bicyclic compounds for use as rip1 kinase inhibitors
MY194711A (en) Novel annelated phenoxyacetamides
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2016014946A (es) Derivados de carboxamida.
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
PH12020550763A1 (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
MX379373B (es) Derivado de sulfonamida heterocíclico y medicina que contiene el mismo.
MY194941A (en) C-glycoside derivatives having fused phenyl ring or pharmaceutically acceptable salts thereof, method for preparing the same and pharmaceutical composition comprising the same
PH12020500120A1 (en) Pharmaceutical compositions
PH12020500233A1 (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
BR112017025356A2 (pt) composto, composição farmacêutica, e, fármaco.
EA201891136A1 (ru) Фармацевтическая композиция, содержащая в качестве активного ингредиента производное 7-азаиндолин-2-она или его фармацевтически приемлемую соль
TR201722852A2 (tr) Mesalazi̇ni̇n oral farmasöti̇k kompozi̇syonlari
MX2018007272A (es) Composicion farmaceutica de liberacion pulsatil que comprende naftazona o una de sus sales.
PH12016502247A1 (en) Carboxamide derivatives